Table of Contents : Hepatitis B Annual : 2004 - 1(1) 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.HBV: Your help needed please....
Liaquat AliHepatitis B Annual 2012 9(1):94-96 (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 3, 2016 Category: Hematology Authors: Liaquat Ali Source Type: research
Nonalcoholic fatty liver disease and hepatitis B virus infection
Bijay Misra, Shivaram Prasad SinghHepatitis B Annual 2012 9(1):86-93Nonalcoholic fatty liver disease [NAFLD] has rapidly emerged as the most common liver disorder not only in developed countries, but also in the developing countries. This entity encompasses a wide variety of liver abnormalities ranging from plain hepatic steatosis through nonalcoholic steatohepatitis [NASH] to cirrhosis of the liver and hepatocellular carcinoma [HCC]. NAFLD is now recognized as the hepatic manifestation of insulin resistance [IR], and an important marker of the metabolic syndrome [MS]. Although a number of advances have been made in elucid...
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 3, 2016 Category: Hematology Authors: Bijay Misra Shivaram Prasad Singh Source Type: research
Overview of the histopathology of chronic hepatitis B infection
This article provides an overview of the histopathology of chronic hepatitis B virus infection. (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 3, 2016 Category: Hematology Authors: Prasenjit Das Arvind Ahuja Siddhartha Datta Gupta Source Type: research
Antituberculosis therapy in patients with hepatitis B viral infection
This article reviews the epidemiology and management of co-infection with Tuberculosis (TB) and Hepatitis B virus (HBV) and the hepatotoxicity due to ATT. (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 3, 2016 Category: Hematology Authors: Nikhil D Patel Shivaram Prasad Singh Source Type: research
Spectrum of hepatitis B infection in Southern India: A cross-sectional analysis
Conclusion: A significant proportion of HBsAg-positive patients is in inactive or in immunotolerant phase and do not require treatment. Patients with elevated ALT and HBV DNA levels need further evaluation to categorize them into immune clearance or immune reactive phase. (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 3, 2016 Category: Hematology Authors: Sivasubramaniam Balasubramanian Arulselvan Velusamy Arunkumar Krishnan Jayanthi Venkatraman Source Type: research
The South Asian cauldron: Hepatitis B, NAFLD, tuberculosis and .. & #8230;..
Shivaram Prasad Singh, Sudha Kumari SinghHepatitis B Annual 2012 9(1):1-3 (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 3, 2016 Category: Hematology Authors: Shivaram Prasad Singh Sudha Kumari Singh Source Type: research
HBV: Your help needed please....
Liaquat AliHepatitis B Annual 2012 9(1):94-96 (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 1, 2016 Category: Hematology Authors: Liaquat Ali Source Type: research
Nonalcoholic fatty liver disease and hepatitis B virus infection
Bijay Misra, Shivaram Prasad SinghHepatitis B Annual 2012 9(1):86-93Nonalcoholic fatty liver disease [NAFLD] has rapidly emerged as the most common liver disorder not only in developed countries, but also in the developing countries. This entity encompasses a wide variety of liver abnormalities ranging from plain hepatic steatosis through nonalcoholic steatohepatitis [NASH] to cirrhosis of the liver and hepatocellular carcinoma [HCC]. NAFLD is now recognized as the hepatic manifestation of insulin resistance [IR], and an important marker of the metabolic syndrome [MS]. Although a number of advances have been made in elucid...
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 1, 2016 Category: Hematology Authors: Bijay Misra Shivaram Prasad Singh Source Type: research
Overview of the histopathology of chronic hepatitis B infection
This article provides an overview of the histopathology of chronic hepatitis B virus infection. (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 1, 2016 Category: Hematology Authors: Prasenjit Das Arvind Ahuja Siddhartha Datta Gupta Source Type: research
Antituberculosis therapy in patients with hepatitis B viral infection
This article reviews the epidemiology and management of co-infection with Tuberculosis (TB) and Hepatitis B virus (HBV) and the hepatotoxicity due to ATT. (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 1, 2016 Category: Hematology Authors: Nikhil D Patel Shivaram Prasad Singh Source Type: research
Spectrum of hepatitis B infection in Southern India: A cross-sectional analysis
Conclusion: A significant proportion of HBsAg-positive patients is in inactive or in immunotolerant phase and do not require treatment. Patients with elevated ALT and HBV DNA levels need further evaluation to categorize them into immune clearance or immune reactive phase. (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 1, 2016 Category: Hematology Authors: Sivasubramaniam Balasubramanian Arulselvan Velusamy Arunkumar Krishnan Jayanthi Venkatraman Source Type: research
The South Asian cauldron: Hepatitis B, NAFLD, tuberculosis and .. & #8230;..
Shivaram Prasad Singh, Sudha Kumari SinghHepatitis B Annual 2012 9(1):1-3 (Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1))
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - November 1, 2016 Category: Hematology Authors: Shivaram Prasad Singh Sudha Kumari Singh Source Type: research
Telbivudine: A valuable treatment option in chronic hepatitis B
Shivaram Prasad Singh, Parimal LawateHepatitis B Annual 2011 8(1):84-106The last five years have emerged as a new era in the treatment of chronic hepatitis B (CHB). Advances in therapeutics and the approval of new drugs have been accompanied by a better understanding of the natural history and pathogenesis, as well as better diagnostics. In the treatment of CHB, no therapy has been proven to eradicate the virus completely from the human body due to the persistence of the covalently closed circular hepatitis B virus (HBV) DNA in the hepatocytes. Long-term maximal viral suppression is of utmost importance for the prevention ...
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - September 7, 2016 Category: Hematology Authors: Shivaram Prasad Singh Parimal Lawate Source Type: research
Interferon for HBV infection: Plain or Pegylated ? Alone or in combination ? Concurrent or sequential ?
Ajit Sood, Vandana MidhaHepatitis B Annual 2011 8(1):71-83Hepatitis B Virus (HBV) infection is a significant global public health problem. Treatment options that have evolved rapidly over the last two decades have proven to be effective, but clear recommendations regarding the choice of first-line therapy are lacking. With the emergence of pegylated interferon (PEG IFN), conventional interferon has been relegated into the background and has a very limited role in the treatment of chronic Hepatitis B. Pegylated interferon α2a / 2b treatment has been documented to successfully achieve normalization of alanine ami...
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - September 7, 2016 Category: Hematology Authors: Ajit Sood Vandana Midha Source Type: research
Management of chronic hepatitis B
Rohit Goyal, Subrat K AcharyaHepatitis B Annual 2011 8(1):32-70Hepatitis B virus (HBV) is the most important cause of chronic liver disease and hepatocellular carcinoma in India. During the past three decades, considerable advances in the diagnosis and treatment of HBV infection have been achieved. However, despite the remarkable improvements, medical management for HBV induced cirrhosis, and liver cancer remains unsatisfactory. In fact, it is becoming increasingly clear that as of now, there is no "cure" for hepatitis B infection. Management of chronic hepatitis B has changed considerably; currently, emphasis is...
Source: Table of Contents : Hepatitis B Annual : 2004 - 1(1) - September 7, 2016 Category: Hematology Authors: Rohit Goyal Subrat K Acharya Source Type: research
